[1] Deslypere G, Gullentops D, Wauters E, et al.  Immunotherapy in non-metastatic non-small cell lung cancer: can the benefits of stage Ⅳ therapy be translated into earlier stages?[J]. Ther Adv Med Oncol, 2018, 10: 1-11-.   doi: 10.1177/1758835918772810
[2] Cheng G, Huang H.  Prognostic value of 18F-fluorodeoxyglucose PET/computed tomography in non-small-cell lung cancer[J]. PET Clin, 2018, 13(1): 59-72.   doi: 10.1016/j.cpet.2017.08.006
[3] Paesmans M, Berghmans T, Dusart M, et al.  Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project[J]. J Thorac Oncol, 2010, 5(5): 612-619.   doi: 10.1097/JTO.0b013e3181d0a4f5
[4]

Liu J, Dong M, Sun X, et al. Prognostic value of 18F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis[J/OL]. PLoS One, 2016, 11(1): e0146195[2019-08-27]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699812. DOI: 10.1371/journal.pone.0146195.
[5] Paesmans M, Garcia C, Wong CYO, et al.  Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data[J]. Eur Respir J, 2015, 46(6): 1751-1761.   doi: 10.1183/13993003.00099-2015
[6] Konings R, van Gool MH, Bard MPL, et al.  Prognostic value of pre-operative glucose-corrected maximum standardized uptake value in patients with non-small cell lung cancer after complete surgical resection and 5-year follow-up[J]. Ann Nucl Med, 2016, 30(5): 362-368.   doi: 10.1007/s12149-016-1070-2
[7] Murakami S, Saito H, Sakuma Y, et al.  Prognostic value of preoperative FDG-PET in stage IA lung adenocarcinoma[J]. Eur J Radiol, 2012, 81(8): 1891-1895.   doi: 10.1016/j.ejrad.2011.04.007
[8] Ohtaki Y, Shimizu K, Kaira K, et al.  Risk factors associated with recurrence of surgically resected node-positive non-small cell lung cancer[J]. Surg Today, 2016, 46(10): 1196-1208.   doi: 10.1007/s00595-015-1301-5
[9] de Jong WK, van der Heijden HFM, Pruim J, et al.  Prognostic value of different metabolic measurements with fluorine-18 fluorodeoxyglucose positron emission tomography in resectable non-small cell lung cancer: a two-center study[J]. J Thorac Oncol, 2007, 2(11): 1007-1012.   doi: 10.1097/JTO.0b013e31815608f5
[10] Liu S, Yin H, Ji HY, et al.  Overexpression of TRIM44 is an independent marker for predicting poor prognosis in epithelial ovarian cancer[J]. Exp Ther Med, 2018, 16(4): 3034-3040.   doi: 10.3892/etm.2018.6541
[11] Agarwal M, Brahmanday G, Bajaj SK, et al.  Revisiting the prognostic value of preoperative 18F-fluoro-2-deoxyglucose 18F-FDG positron emission tomography (PET) in early-stage (Ⅰ & Ⅱ) non-small cell lung cancers (NSCLC)[J]. Eur J Nucl Med Mol Imaging, 2010, 37(4): 691-698.   doi: 10.1007/s00259-009-1291-x
[12]

Horne ZD, Clump DA, Vargo JA, et al. Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy[J]. Radiat Oncol, 2014, 9: 41[2019-08-27]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922961. DOI: 10.1186/1748-717X-9-41.
[13] Lee VHF, Chan WWL, Lee EYP, et al.  Prognostic significance of standardized uptake value of lymph nodes on survival for stage Ⅲ non-small cell lung cancer treated with definitive concurrent chemoradiotherapy[J]. Am J Clin Oncol, 2016, 39(4): 355-362.   doi: 10.1097/COC.0000000000000070
[14]

Carvalho S, Leijenaar RTH, Troost EGC, et al. 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC)-a prospective externally validated study[J/OL]. PLoS One, 2018, 13(3): e192859[2019-08-27]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832210. DOI: 10.1371/journal.pone.0192859.
[15] Sasaki R, Komaki R, Macapinlac H, et al.  [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non–small-cell lung cancer[J]. J Clin Oncol, 2005, 23(6): 1136-1143.   doi: 10.1200/JCO.2005.06.129
[16] 王涛, 王振光.  18F-FDG PET/CT代谢参数在非小细胞肺癌预后评估中的应用及进展[J]. 中国肺癌杂志, 2019, 22(3): 167-172.   doi: 10.3779/j.issn.1009-3419.2019.03.09
Wang T, Wang ZG.  Application of metabolic parameters measured by 18F-FDG PET/CT in the evaluation of the prognosis of non-small cell lung cancer[J]. Chin J Lung Cancer, 2019, 22(3): 167-172.   doi: 10.3779/j.issn.1009-3419.2019.03.09
[17] Bazan JG, Duan FH, Snyder BS, et al.  Metabolic tumor volume predicts overall survival and local control in patients with stage Ⅲ non-small cell lung cancer treated in ACRIN 6668/RTOG 0235[J]. Eur J Nucl Med Mol Imaging, 2017, 44(1): 17-24.   doi: 10.1007/s00259-016-3520-4
[18] Zhang H, Wroblewski K, Appelbaum D, et al.  Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer[J]. Int J Comput Assist Radiol Surg, 2013, 8(2): 181-191.   doi: 10.1007/s11548-012-0749-7
[19] Aktas GE, Karamustafaoğlu YA, Balta C, et al.  Prognostic significance of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography-derived metabolic parameters in surgically resected clinical-no nonsmall cell lung cancer[J]. Nucl Med Commun, 2018, 39(11): 995-1004.   doi: 10.1097/MNM.0000000000000903
[20] 郑庆中, 苏洁敏, 邓菁, 等.  18F-FDG PET/CT代谢参数对116例非小细胞肺癌患者预后评估价值[J]. 中华肿瘤防治杂志, 2020, 27(16): 1309-1314.   doi: 10.16073/j.cnki.cjcpt.2020.16.06
Zheng QZ, Su JM, Deng J, et al.  Prognostic value of 18F-FDG PET/CT metabolic parameters in patients with non-small cell lung cancer[J]. Chin J Cancer Prev Treat, 2020, 27(16): 1309-1314.   doi: 10.16073/j.cnki.cjcpt.2020.16.06
[21] Burger IA, Vargas HA, Apte A, et al.  PET quantification with a histogram derived total activity metric: superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients[J]. Nucl Med Biol, 2014, 41(5): 410-418.   doi: 10.1016/j.nucmedbio.2014.02.006
[22] Im HJ, Pak K, Cheon GJ, et al.  Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis[J]. Eur J Nucl Med Mol Imaging, 2015, 42(2): 241-251.   doi: 10.1007/s00259-014-2903-7
[23] 陈挺, 张宏, 田梅, 等.  18F-FDG PET/CT代谢半定量参数在非小细胞肺癌预后评估中的价值[J]. 国际放射医学核医学杂志, 2018, 42(3): 269-273.   doi: 10.3760/cma.j.issn.1673-4114.2018.03.014
Chen T, Zhang H, Tian M, et al.  Prognostic evaluation of patients with non-small cell lung cancer by using semi-quantitative metabolic parameters of 18F-FDG PET/CT[J]. Int J Radiat Med Nucl Med, 2018, 42(3): 269-273.   doi: 10.3760/cma.j.issn.1673-4114.2018.03.014
[24] Kim K, Kim SJ, Kim I J, et al.  Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer[J]. Nucl Med Commun, 2012, 33(6): 613-620.   doi: 10.1097/MNM.0b013e328351d4f5